Gill Mundin

Low absolute bioavailability of oral naloxone in healthy subjects

Kevin J. Smith, Michael Hopp, Gill Mundin et al. · International Journal of Clinical Pharmacology and Therapeutics · 2012 · 100 citations

Pharmacy, Pharmacokinetics, Pharmacology +16

Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study

Rebecca McDonald, Ulrike Lorch, Jo Woodward et al. · Addiction · 2017 · 97 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15

Preclinical Characterization of AZD9574, a Blood–Brain Barrier Penetrant Inhibitor of PARP1

Anna D. Staniszewska, Domenic Pilger, Sonja J. Gill et al. · Clinical Cancer Research · 2023 · 58 citations

Medicine, Oncology, Pharmacology +14

Naloxone as part of a prolonged release oxycodone/naloxone combination reduces oxycodone-induced slowing of gastrointestinal transit in healthy volunteers

Kevin J. Smith, Michael Hopp, Gill Mundin et al. · Expert Opinion on Investigational Drugs · 2011 · 55 citations

Medicine, Pharmacology, Pharmacotherapy +17

Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers

Kevin J. Smith, Michael Hopp, Gill Mundin et al. · Clinical Therapeutics · 2008 · 49 citations

Medicine, Pharmacokinetics, Pharmacology +16